Moderna, Inc. Finance Lease, Interest Payment on Liability
Moderna, Inc. (MRNA) reported Finance Lease, Interest Payment on Liability of $3.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FinanceLeaseInterestPaymentOnLiability · last filed 2026-02-20
- Moderna, Inc. finance lease, interest payment on liability for the quarter ending 2020-12-31 was $3.62M, a 154.00% increase year-over-year.
- Moderna, Inc. finance lease, interest payment on liability for the quarter ending 2020-09-30 was $2.43M, a 75.13% increase year-over-year.
- Moderna, Inc. finance lease, interest payment on liability for the quarter ending 2020-06-30 was $1.53M, a 10.24% increase year-over-year.
- Moderna, Inc. finance lease, interest payment on liability for the quarter ending 2020-03-31 was $1.43M, a 2.74% increase year-over-year.
- Moderna, Inc. finance lease, interest payment on liability for fiscal 2025 was $3.00M, a 84.21% decline from fiscal 2024.
- Moderna, Inc. finance lease, interest payment on liability for fiscal 2024 was $19.00M, a 51.28% decline from fiscal 2023.
- Moderna, Inc. finance lease, interest payment on liability for fiscal 2023 was $39.00M, a 56.00% increase from fiscal 2022.
- Moderna, Inc. finance lease, interest payment on liability for fiscal 2022 was $25.00M, a 78.57% increase from fiscal 2021.
| Period end | Finance Lease, Interest Payment on Liability 3 month | Finance Lease, Interest Payment on Liability 6 month | Finance Lease, Interest Payment on Liability 9 month | Finance Lease, Interest Payment on Liability 12 month | Finance Lease, Interest Payment on Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $3.00M 10-K · filed 2026-02-20 | ||||
| 2024-12-31 | $19.00M 10-K · filed 2026-02-20 | ||||
| 2023-12-31 | $39.00M 10-K · filed 2026-02-20 | ||||
| 2022-12-31 | $25.00M 10-K · filed 2025-02-21 | ||||
| 2021-12-31 | $14.00M 10-K · filed 2024-02-23 | ||||
| 2020-12-31 | $3.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $6.05M derived: sum of 2 quarters · filed 2023-02-24 | $7.58M derived: sum of 3 quarters · filed 2023-02-24 | $9.00M 10-K · filed 2023-02-24 | $8.52M 10-K · filed 2021-02-26 |
| 2020-09-30 | $2.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $3.96M derived: sum of 2 quarters · filed 2020-10-30 | $5.38M 10-Q · filed 2020-10-30 | $6.81M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2020-06-30 | $1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.95M 10-Q · filed 2020-08-06 | $4.38M derived: sum of 3 quarters · filed 2021-02-26 | $5.76M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2020-03-31 | $1.43M 10-Q · filed 2020-05-07 | $2.85M derived: sum of 2 quarters · filed 2021-02-26 | $4.24M derived: sum of 3 quarters · filed 2021-02-26 | $5.62M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $2.81M derived: sum of 2 quarters · filed 2021-02-26 | $4.20M derived: sum of 3 quarters · filed 2021-02-26 | $5.58M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $2.77M derived: sum of 2 quarters · filed 2020-10-30 | $4.16M 10-Q · filed 2020-10-30 | ||
| 2019-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.77M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $1.39M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |